The
United Kingdom In Vitro Diagnostics Market is anticipated to grow significantly
in the projected period, 2024-2028. The United Kingdom in vitro diagnostics
market has experienced steady growth over the years, driven by factors such as
an aging population, rising chronic diseases, and a focus on early detection
and preventive care. The market encompasses a wide range of tests and
technologies, including clinical chemistry, immunochemistry, molecular
diagnostics, point-of-care testing, hematology, and microbiology, among others.
Testing
carried out on human bodily tissue or blood samples is known as in vitro
diagnostics (IVD). In vitro diagnostics can be used to monitor a person's
overall health, diagnose diseases or other disorders, and help treat, prevent,
or cure illnesses. Precision medicine may also make use of in vitro diagnostics
to pinpoint patients who will likely benefit from particular medications or
treatments, leading to the growth of the United Kingdom In Vitro Diagnostics
Market. Next-generation sequencing tests, which scan a person's DNA to find
genetic changes, can be a part of these in vitro diagnostics.
Rapid
advancements in diagnostic technologies, such as next-generation sequencing,
digital pathology, and lab automation, will revolutionize the in vitro
diagnostics landscape. These innovations will enable faster and more accurate
diagnoses, leading to improved patient outcomes and cost-effective healthcare,
hence augmenting the growth of the United Kingdom In Vitro Diagnostics Market.
According
to the Office for National Statistics, the cost of healthcare in the UK was
estimated to be around USD350.83 billion in 2022, a rise in nominal terms of
0.7% over 2021. For
chronic disorders to be treated quickly and effectively, early detection is
essential. As a result, it is anticipated that demand for in-vitro diagnostic
testing would rise. According to the International Agency for Research on
Cancer, 51,983 new cases of lung cancer were reported in the United Kingdom in
2020, accounting for 11.8% of the total new cancer cases, which is 457,960.
In-vitro
diagnostics is in high demand due to the need for early diagnosis and
monitoring of various disorders utilizing imaging technologies for better
disease management and treatment planning. This has resulted in a boom in the
in-vitro diagnostics market in the United Kingdom.
The
United Kingdom's population is aging quickly. According to the Office of
National Statistics, almost 11 million persons, or 18.6% of the total
population, were 65 years of age or older in 2021, compared to 16.4% at the
time of the previous census in 2011. The need for in-vitro diagnostic tests
is anticipated to increase since chronic diseases are more prevalent in the
elderly. Additionally, the government of the United Kingdom is launching
programs to raise awareness of the advantages of early detection, which is
expected to drive the United Kingdom In Vitro Diagnostics Market in the
forecast period.
Recent
Advancements in Pharmacogenomics Drive United Kingdom's In Vitro Diagnostics
Market
In
the United Kingdom, recent advancements in pharmacogenomics have been
instrumental in driving the growth of the in vitro diagnostics (IVD) market.
Pharmacogenomics, the study of how an individual's genetic makeup influences
their response to drugs, has revolutionized the field of healthcare. By
combining genetics and genomics with traditional medicine, pharmacogenomics
provides personalized treatment options that are tailored to a patient's
genetic profile. This has led to the expansion of the United Kingdom In Vitro
Diagnostics Market.
The
National Health Service (NHS) in the United Kingdom has recognized the
potential of pharmacogenomics and has started implementing guidelines for its
incorporation into clinical practice. These guidelines help healthcare
professionals make informed decisions based on a patient's genetic information,
improving treatment outcomes and patient safety. Pharmacogenomics will be
included in the ordinary National Health Service practice to provide patients
with safer and more effective treatments, and to prevent wasting time and money
on procedures that may be unsuccessful or even hazardous.
The
development of high-throughput DNA sequencing and genotyping technologies has
made it possible to rapidly and cost-effectively analyze an individual's
genetic profile. These advancements have facilitated the integration of
pharmacogenomics into routine clinical practice, thereby augmenting the growth
of the United Kingdom In Vitro Diagnostics Market.
Rising Geriatric Population Revolutionize the United
Kingdom In Vitro Diagnostics Market
The demand for IVD tests is anticipated to increase
because chronic diseases are more prevalent in the elderly. Early diagnosis is
essential for effective treatment in the geriatric population, which is why the
United Kingdom In-vitro Diagnostics Market is growing. The geriatric population
frequently suffers from multiple chronic diseases such as diabetes,
cardiovascular conditions, and cancer. According to the House of Commons
Library, the older population in the United Kingdom will increase, accounting
for 24% of the total population (17.4 million people) by 2043. The percentage
of people aged 75 and older is anticipated to increase from 8% in 2018 to 13%
in 2043, while the percentage of people aged 85 and older is anticipated to
increase from 2% to 4%.
Prevalence of Infectious Diseases
Infectious diseases pose a significant burden on
public health systems and economies worldwide. The United Kingdom has faced
outbreaks of diseases such as influenza, tuberculosis, hepatitis, sexually
transmitted infections, and, recently, the COVID-19 pandemic. These outbreaks
have highlighted the importance of rapid and accurate diagnostics for effective
disease control and management. According to the Office of National Statistics
2019, allergy was the most frequently reported chronic health condition in both
men and women (30.4% and 36.0%, respectively), followed by high blood pressure,
low back disorder, and depression as the four most prevalent chronic conditions
in the United Kingdom. In addition to having a negative impact on people's
quality of life, chronic diseases place a heavy financial burden on the
healthcare system. To facilitate early and accurate diagnosis of chronic
diseases, monitor disease progression, and inform treatment choices, there has
been an increasing demand for advanced in-vitro diagnostic technologies in the
United Kingdom. This has caused the market for in-vitro diagnostics to grow in
the United Kingdom, where a variety of modalities are being used. The growing
understanding of the value of early disease detection and prevention is another
factor influencing the growth of the in-vitro diagnostics market in the United
Kingdom.
Download Free Sample Report
Recent Developments
- In
January 2023, the majority of in-vitro diagnostic (IVD) devices will be
evaluated by UL International UK Ltd, according to the Medicines and
Healthcare products Regulatory Agency (MHRA). This will boost the United
Kingdom's capacity to handle conformity assessments and ensure that safe
and effective IVDs are available to UK citizens.
- In July
2022, Siemens Healthineers unveiled The Atellica CI 1900 Analyzer, a
clinical chemistry and immunoassay testing system. It is a lower volume
variant of their currently marketed Atellica clinical chemistry and
immunoassay testing solution. The system has the ability to perform over 25,000
immunoassay tests annually and over 250,000 clinical chemistry tests
annually. According to Siemens Healthineers, the new analyzer can be used
as a stand-alone system in hub-and-spoke configurations connected to
integrated delivery networks.
Mergers and Collaborations
- In March 2023, Agilent and Sophia
Genetics collaborated to develop a cancer analysis solution. The
partnership will integrate Agilent's SureSelect Cancer CGP Assay Kit and
the SOPHiA DDM Platform, enabling clinical researchers to accurately
identify a variety of biomarkers. This integration will reduce the
possibility of omitting important information in cancer sample analysis.
Market
Segmentation
The United Kingdom In Vitro Diagnostics Market is
segmented by Product, Test Type, Usability, Application, End User, Region, and
Competitive Landscape. Regarding Product, the market is divided into Instrument,
Reagent, and Other Products. Test Types include Clinical Chemistry, Molecular
Diagnostics, Hematology, Immuno Diagnostics, and Other Types. Usability category
consist of Disposable In Vitro Diagnostics Devices and Reusable In vitro
Diagnostics Devices. The Application segment includes Infectious Disease,
Diabetes, Oncology, Cardiology, Autoimmune Disease, Nephrology, and others. End
Users are categorized as Diagnostic Laboratories, Hospitals & Clinics, and
Others. The market is further segmented by region, including Scotland,
South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and
East Midlands.
Company
Profiles
F. Hoffmann-La Roche Ltd., Abbott Laboratories, bioMérieux
UK, Becton Dickinson and Company, Danaher Corporation, Agilent Technologies,
Inc., Sysmex UK Ltd, Siemens Healthineers, Charles River Laboratories, Bio-Rad
Laboratories, Inc are some of the key players of United Kingdom In Vitro
Diagnostics market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
company shares, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Product
Test Type
Usability
Application
End User
Region
|
|
Country scope
|
Scotland,
South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and
East Midlands
|
|
Key companies
profiled
|
F. Hoffmann-La Roche Ltd., Abbott Laboratories, bioMérieux UK, Becton
Dickinson and Company, Danaher Corporation, Agilent Technologies, Inc.,
Sysmex UK Ltd, Siemens Healthineers, Charles River Laboratories, Bio-Rad Laboratories
|
|
Customization scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide the
editable version of the report in PPT/Word format on special request)
|
Report
Scope:
In
this report, United Kingdom In Vitro Diagnostics Market has been segmented into
the following categories, in addition to the industry trends, which have also
been detailed below:
- United
Kingdom In-vitro Diagnostics Market,
By Product:
- Instrument
- Reagent
- Other Products
- United
Kingdom In-vitro Diagnostics Market,
By Test Type:
- Clinical Chemistry
- Molecular Diagnostics
- Hematology
- Immuno Diagnostics
- Other Types
- United
Kingdom In-vitro Diagnostics Market,
By Usability:
- Disposable In Vitro Diagnostics Devices
- Reusable In vitro Diagnostics Devices
- United
Kingdom In-vitro Diagnostics Market,
By Application:
- Infectious Disease
- Diabetes
- Oncology
- Cardiology
- Autoimmune Disease
- Nephrology
- Others
- United
Kingdom In-vitro Diagnostics Market,
By End User:
- Diagnostic Laboratories
- Hospitals & Clinics
- Others
- United Kingdom In Vitro Diagnostics Market, By
Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire & Humberside
- East Midlands
Competitive
landscape
Company
Profiles: Detailed
analysis of the major companies in United Kingdom In Vitro Diagnostics market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed
analysis and profiling of additional market players (up to five).
United
Kingdom In Vitro Diagnostics Market is an upcoming report to be released soon.
If you wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]